Pharsight

Drug Patents Expiring in 2033

1. Abilify Asimtufii patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10517951 OTSUKA Injectable preparation
Apr, 2033

(9 years from now)

US11638757 OTSUKA Injectable preparation
Apr, 2033

(9 years from now)

US11097007 OTSUKA Injectable preparation
Apr, 2033

(9 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 27 April, 2023

Treatment: Maintenance monotherapy treatment of bipolar i disorder; Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

ABILIFY ASIMTUFII family patents

Family Patents

2. Abilify Maintena Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11400087 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Sep, 2033

(9 years from now)

US10980803 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Sep, 2033

(9 years from now)

US11154553 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Sep, 2033

(9 years from now)

US11344547 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Sep, 2033

(9 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 28 February, 2013

Treatment: Maintenance monotherapy treatment of bipolar i disorder; Treatment of schizophrenia; Treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

How can I launch a generic of ABILIFY MAINTENA KIT before it's drug patent expiration?
More Information on Dosage

ABILIFY MAINTENA KIT family patents

Family Patents

3. Abilify Mycite Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9268909 OTSUKA Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device
Oct, 2033

(9 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 13 November, 2017

Treatment: Method of using a logic circuit to stabilize battery voltage supplied to a sensor embedded with a tablet and that communicates information via a signal through the body of a patient to a receiver

Dosage: TABLET;ORAL

More Information on Dosage

ABILIFY MYCITE KIT family patents

Family Patents

4. Aczone patents expiration

ACZONE Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9517219 ALMIRALL Topical dapsone and dapsone/adapalene compositions and methods for use thereof
Nov, 2033

(9 years from now)

US9161926 ALMIRALL Topical dapsone and dapsone/adaplene compositions and methods for use thereof
Nov, 2033

(9 years from now)

US11273132 ALMIRALL Topical dapsone and dapsone/adapalene compositions and methods for use thereof
Nov, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Sep 10, 2022

Drugs and Companies using DAPSONE ingredient

Market Authorisation Date: 24 February, 2016

Treatment: Topical treatment of acne vulgaris

Dosage: GEL;TOPICAL

How can I launch a generic of ACZONE before it's drug patent expiration?
More Information on Dosage

ACZONE family patents

Family Patents

5. Agamree patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11690853 CATALYST PHARMS Non-hormonal steroid modulators of NF-κβ for treatment of disease
Mar, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 26, 2028
Orphan Drug Exclusivity (ODE) Oct 26, 2030

Drugs and Companies using VAMOROLONE ingredient

NCE-1 date: 2027-10-27

Market Authorisation Date: 26 October, 2023

Treatment: Treatment of duchenne muscular dystrophy

Dosage: SUSPENSION;ORAL

More Information on Dosage

AGAMREE family patents

Family Patents

6. Aklief patents expiration

AKLIEF's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9498465 GALDERMA LABS LP Topical compositions in the form of a gel containing a particular solubilized retinoid
May, 2033

(9 years from now)

US9084778 GALDERMA LABS LP Topical compositions containing a retinoid of the oil-in-water emulsion type
May, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 4, 2024

Drugs and Companies using TRIFAROTENE ingredient

NCE-1 date: 2023-10-05

Market Authorisation Date: 04 October, 2019

Treatment: Topical treatment of acne vulgaris; Treatment of acne vulgaris

Dosage: CREAM;TOPICAL

More Information on Dosage

AKLIEF family patents

Family Patents

7. Alkindi Sprinkle patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9675559 ETON Treatment of adrenal insufficiency
Jan, 2033

(8 years from now)

Drugs and Companies using HYDROCORTISONE ingredient

Market Authorisation Date: 29 September, 2020

Treatment: Treatment of adrenal insufficiency

Dosage: GRANULE;ORAL

More Information on Dosage

ALKINDI SPRINKLE family patents

Family Patents

8. Antara (micronized) patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9314447 LUPIN Reduced dose pharmaceutical compositions of fenofibrate
May, 2033

(9 years from now)

Drugs and Companies using FENOFIBRATE ingredient

Market Authorisation Date: 30 November, 2004

Treatment: Treating primary hypercholesterolemia and mixed dyslipidemia; Treating severe hypertriglyceridemia

Dosage: CAPSULE;ORAL

How can I launch a generic of ANTARA (MICRONIZED) before it's drug patent expiration?
More Information on Dosage

ANTARA (MICRONIZED) family patents

Family Patents

9. Aristada patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9193685 ALKERMES INC Pharmaceutical compositions having improved storage stability
Oct, 2033

(9 years from now)

US11097006 ALKERMES INC Pharmaceutical compositions having improved storage stability
Oct, 2033

(9 years from now)

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Market Authorisation Date: 05 October, 2015

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

ARISTADA family patents

Family Patents

10. Arymo Er patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9044402 ZYLA Abuse-deterrent pharmaceutical compositions for controlled release
Jul, 2033

(9 years from now)

US9549899 ZYLA Abuse deterrent pharmaceutical compositions for controlled release
Jul, 2033

(9 years from now)

Drugs and Companies using MORPHINE SULFATE ingredient

Market Authorisation Date: 09 January, 2017

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of ARYMO ER before it's drug patent expiration?
More Information on Dosage

ARYMO ER family patents

Family Patents

11. Austedo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9550780 TEVA BRANDED PHARM Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9233959 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(9 years from now)

US9296739 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(9 years from now)

US9814708 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(9 years from now)

US11666566 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 3, 2024
M (M) Jun 24, 2024
Pediatric Exclusivity (PED) Dec 24, 2024

Drugs and Companies using DEUTETRABENAZINE ingredient

Market Authorisation Date: 03 April, 2017

Treatment: Treatment of tardive dyskinesia; A method of treating huntington's chorea

Dosage: TABLET;ORAL

How can I launch a generic of AUSTEDO before it's drug patent expiration?
More Information on Dosage

AUSTEDO family patents

Family Patents

12. Austedo Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9550780 TEVA Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(9 years from now)

Drugs and Companies using DEUTETRABENAZINE ingredient

Market Authorisation Date: 17 February, 2023

Treatment: Treatment of tardive dyskinesia; A method of treating huntington's chorea

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

AUSTEDO XR family patents

Family Patents

13. Auvelity patents expiration

Can you believe AUVELITY received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8569328 AXSOME Compositions and methods comprising tilidine or related compounds and dextromethorphan
Oct, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Aug 18, 2025

Drugs and Companies using BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE ingredient

Market Authorisation Date: 18 August, 2022

Treatment: Dextromethorphan and bupropion in combination to treat major depressive disorder

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of AUVELITY before it's drug patent expiration?
More Information on Dosage

AUVELITY family patents

Family Patents

14. Balversa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8895601 JANSSEN BIOTECH Pyrazolyl quinoxaline kinase inhibitors
Apr, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 12, 2024

Drugs and Companies using ERDAFITINIB ingredient

NCE-1 date: 2023-04-13

Market Authorisation Date: 12 April, 2019

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of BALVERSA before it's drug patent expiration?
More Information on Dosage

BALVERSA family patents

Family Patents

15. Baxdela patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9493582 MELINTA Alkylated cyclodextrin compositions and processes for preparing and using the same
Feb, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 19, 2022
Generating Antibiotic Incentives Now (GAIN) Jun 19, 2027

Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient

NCE-1 date: 2026-06-19

Market Authorisation Date: 19 June, 2017

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

BAXDELA family patents

Family Patents

16. Belsomra patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10098892 MERCK SHARP DOHME Solid dosage formulations of an orexin receptor antagonist
May, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Jan 29, 2023

Drugs and Companies using SUVOREXANT ingredient

Market Authorisation Date: 13 August, 2014

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

BELSOMRA family patents

Family Patents

17. Bendeka patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9144568 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(9 years from now)

US10052385 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(9 years from now)

US9597399 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(9 years from now)

US9034908 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(9 years from now)

US9597397 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(9 years from now)

US9572887 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(9 years from now)

US9579384 EAGLE PHARMS Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
Mar, 2033

(9 years from now)

US9000021 EAGLE PHARMS Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
Mar, 2033

(9 years from now)

US9597398 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 7, 2022

Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 07 December, 2015

Treatment: For use in the treatment of patients with chronic lymphocytic leukemia and/or non-hodgkins lymphoma; For the treatment of patients with indolent b-cell non-hodgkin lymphoma; For the treatment of patie...

Dosage: SOLUTION;IV (INFUSION)

How can I launch a generic of BENDEKA before it's drug patent expiration?
More Information on Dosage

BENDEKA family patents

Family Patents

18. Biktarvy patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9216996 GILEAD SCIENCES INC Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections
Dec, 2033

(9 years from now)

US9732092 GILEAD SCIENCES INC Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections
Dec, 2033

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9296769

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(8 years from now)

US8754065

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Oct 7, 2028
M (M) Feb 24, 2024

Drugs and Companies using BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Market Authorisation Date: 07 February, 2018

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of BIKTARVY before it's drug patent expiration?
More Information on Dosage

BIKTARVY family patents

Family Patents

19. Bonjesta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9937132 DUCHESNAY Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
Feb, 2033

(9 years from now)

US9375404 DUCHESNAY Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
Feb, 2033

(9 years from now)

US9526703 DUCHESNAY Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
Feb, 2033

(9 years from now)

US9089489 DUCHESNAY Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
Feb, 2033

(9 years from now)

Drugs and Companies using DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE ingredient

Market Authorisation Date: 07 November, 2016

Treatment: Treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of BONJESTA before it's drug patent expiration?
More Information on Dosage

BONJESTA family patents

Family Patents

20. Braftovi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9474754 ARRAY BIOPHARMA INC Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-α inhibitor
Aug, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Oct 11, 2030
New Indication (I) Oct 11, 2026

Drugs and Companies using ENCORAFENIB ingredient

Market Authorisation Date: 27 June, 2018

Treatment: Braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-ap...

Dosage: CAPSULE;ORAL

How can I launch a generic of BRAFTOVI before it's drug patent expiration?
More Information on Dosage

BRAFTOVI family patents

Family Patents

21. Byfavo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9561236 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam)
Apr, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 6, 2025

Drugs and Companies using REMIMAZOLAM BESYLATE ingredient

NCE-1 date: 2024-10-06

Market Authorisation Date: 06 October, 2020

Treatment: Use of remimazolam for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

BYFAVO family patents

Family Patents

22. Cabometyx patents expiration

CABOMETYX's oppositions filed in EPO
Can you believe CABOMETYX received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9724342 EXELIXIS INC C-met modulator pharmaceutical compositions
Jul, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 17, 2028
New Indication (I) Sep 17, 2024

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Market Authorisation Date: 25 April, 2016

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of CABOMETYX before it's drug patent expiration?
More Information on Dosage

CABOMETYX family patents

Family Patents

23. Caplyta patents expiration

Can you believe CAPLYTA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE48839 INTRA-CELLULAR Methods and compositions for sleep disorders and other disorders
Aug, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 20, 2024
New Indication (I) Dec 17, 2024

Drugs and Companies using LUMATEPERONE TOSYLATE ingredient

NCE-1 date: 2023-12-21

Market Authorisation Date: 20 December, 2019

Treatment: Treatment of bipolar depression; Treatment of schizophrenia

Dosage: CAPSULE;ORAL

More Information on Dosage

CAPLYTA family patents

Family Patents

24. Carnexiv patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9493582 LUNDBECK PHARMS LLC Alkylated cyclodextrin compositions and processes for preparing and using the same
Feb, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Oct 7, 2023

Drugs and Companies using CARBAMAZEPINE ingredient

Market Authorisation Date: 07 October, 2016

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

CARNEXIV family patents

Family Patents

25. Cequa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9937225 SUN PHARM Topical formulations and uses thereof
Aug, 2033

(9 years from now)

US10441630 SUN PHARM Topical formulations and uses thereof
Aug, 2033

(9 years from now)

US8980839 SUN PHARM Topical aqueous nanomicellar, ophthalmic solutions and uses thereof
Aug, 2033

(9 years from now)

Drugs and Companies using CYCLOSPORINE ingredient

Market Authorisation Date: 14 August, 2018

Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).

Dosage: SOLUTION;OPHTHALMIC

More Information on Dosage

CEQUA family patents

Family Patents

26. Clorotekal patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9504666 B BRAUN MEDICAL INC Chloroprocaine-based pharmaceutical composition for repeated intrathecal administration
Dec, 2033

(9 years from now)

Drugs and Companies using CHLOROPROCAINE HYDROCHLORIDE ingredient

Market Authorisation Date: 26 September, 2017

Treatment: NA

Dosage: SOLUTION;INTRATHECAL

More Information on Dosage

CLOROTEKAL family patents

Family Patents

27. Complera patents expiration

COMPLERA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10857102 GILEAD SCIENCES INC Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate
Jan, 2033

(8 years from now)

Drugs and Companies using EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE ingredient

Market Authorisation Date: 10 August, 2011

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of COMPLERA before it's drug patent expiration?
More Information on Dosage

COMPLERA family patents

Family Patents

28. Contrave patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11139056 NALPROPION Methods of treating overweight and obesity
Jun, 2033

(9 years from now)

US10403170 NALPROPION Methods of treating overweight and obesity
Jun, 2033

(9 years from now)

US9633575 NALPROPION Methods of treating overweight and obesity
Jun, 2033

(9 years from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 10 September, 2014

Treatment: For chronic weight management for treating overweight or obesity

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of CONTRAVE before it's drug patent expiration?
More Information on Dosage

CONTRAVE family patents

Family Patents

29. Cytalux patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9341629 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(9 years from now)

US9333270 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(9 years from now)

US9061057 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(9 years from now)

US10881747 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(9 years from now)

US9789208 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(9 years from now)

US9254341 ON TARGET LABS Methods of manufacture of pteroyl-amino acid-fluorescent dyes
Oct, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 29, 2026
New Indication (I) Dec 16, 2025
Orphan Drug Exclusivity (ODE) Nov 29, 2028

Drugs and Companies using PAFOLACIANINE SODIUM ingredient

NCE-1 date: 2025-11-29

Market Authorisation Date: 29 November, 2021

Treatment: Cytalux is an optical imaging agent indicated in adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

CYTALUX family patents

Family Patents

30. Daptomycin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10357535 HOSPIRA INC Daptomycin formulations and uses thereof
Sep, 2033

(9 years from now)

US9655946 HOSPIRA INC Daptomycin formulations and uses thereof
Sep, 2033

(9 years from now)

Drugs and Companies using DAPTOMYCIN ingredient

Market Authorisation Date: 21 June, 2021

Treatment: Treatment of complicated skin and skin structure infections and s. aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis by reconstituting and administerin...

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

DAPTOMYCIN family patents

Family Patents

31. Descovy patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9296769

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(8 years from now)

US8754065

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jan 7, 2029

Drugs and Companies using EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Market Authorisation Date: 04 April, 2016

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of DESCOVY before it's drug patent expiration?
More Information on Dosage

DESCOVY family patents

Family Patents

32. Docetaxel patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8940786 SHILPA Non-aqueous taxane nanodispersion formulations and methods of using the same
Sep, 2033

(9 years from now)

US9763880 SHILPA Non-aqueous taxane formulations and methods of using the same
Sep, 2033

(9 years from now)

US9308195 SHILPA Non-aqueous taxane formulations and methods of using the same
Sep, 2033

(9 years from now)

Drugs and Companies using DOCETAXEL ingredient

Market Authorisation Date: 22 December, 2015

Treatment: Method of administering an ethanol-free taxane liquid nanodispersion formulation to a subject combining the formulation with an aqueous medium to provide an ethanol-free taxane diluted solution; Treat...

Dosage: INJECTABLE;INJECTION

More Information on Dosage

DOCETAXEL family patents

Family Patents

33. Empaveli patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11661441 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
Jan, 2033

(8 years from now)

US10125171 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
Aug, 2033

(9 years from now)

US11292815 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
Nov, 2033

(9 years from now)

US10035822 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
Nov, 2033

(9 years from now)

US10875893 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
Nov, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 14, 2026
Orphan Drug Exclusivity (ODE) May 14, 2028
M (M) Feb 8, 2026

Drugs and Companies using PEGCETACOPLAN ingredient

NCE-1 date: 2025-05-14

Market Authorisation Date: 14 May, 2021

Treatment: Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of pegcetacoplan; Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administrat...

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

EMPAVELI family patents

Family Patents

34. Entresto patents expiration

ENTRESTO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11135192 NOVARTIS PHARMS CORP Inhibitors for treating diseases characterized by atrial enlargement or remodeling
Aug, 2033

(9 years from now)

US9937143 NOVARTIS PHARMS CORP Inhibitors for treating diseases characterized by atrial enlargement or remodeling
Aug, 2033

(9 years from now)

US9517226 NOVARTIS PHARMS CORP Inhibitors for treating diseases characterized by atrial enlargement or remodeling
Aug, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Feb 16, 2024

Drugs and Companies using SACUBITRIL; VALSARTAN ingredient

Market Authorisation Date: 07 July, 2015

Treatment: Treatment of heart failure with preserved ejection fraction

Dosage: TABLET;ORAL

How can I launch a generic of ENTRESTO before it's drug patent expiration?
More Information on Dosage

ENTRESTO family patents

Family Patents

35. Epanova patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9050309 ASTRAZENECA DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Jan, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9050308 ASTRAZENECA DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Jan, 2033

(8 years from now)

US10117844 ASTRAZENECA DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Jan, 2033

(8 years from now)

Drugs and Companies using OMEGA-3-CARBOXYLIC ACIDS ingredient

Market Authorisation Date: 05 May, 2014

Treatment: Treatment of hypertriglyceridemia; Treatment of severe hypertriglyceridemia (500 mg/dl) in adult patients as an adjunct to diet

Dosage: CAPSULE;ORAL

More Information on Dosage

EPANOVA family patents

Family Patents

36. Epclusa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8575135

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
May, 2033

(9 years from now)

US8940718

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
May, 2033

(9 years from now)

US8921341

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
May, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 10, 2028
M (M) Apr 27, 2025
Pediatric Exclusivity (PED) Dec 10, 2028

Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient

Market Authorisation Date: 28 June, 2016

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

EPCLUSA family patents

Family Patents

37. Erleada patents expiration

ERLEADA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9481663 JANSSEN BIOTECH Crystalline forms of an androgen receptor modulator
Jun, 2033

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10052314 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Sep, 2033

(9 years from now)

US10849888 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Sep, 2033

(9 years from now)

US9884054 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Sep, 2033

(9 years from now)

USRE49353 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Sep, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 14, 2023

Drugs and Companies using APALUTAMIDE ingredient

NCE-1 date: 2022-02-14

Market Authorisation Date: 14 February, 2018

Treatment: Treatment in combination with a gnrh agonist of non-metastatic, castration-resistant prostate cancer (nm-crpc); Treatment in combination with a gnrh agonist of high risk non-metastatic, castration-res...

Dosage: TABLET;ORAL

How can I launch a generic of ERLEADA before it's drug patent expiration?
More Information on Dosage

ERLEADA family patents

Family Patents

38. Esbriet patents expiration

ESBRIET's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8778947 GENENTECH INC Methods of administering pirfenidone therapy
Aug, 2033

(9 years from now)

Drugs and Companies using PIRFENIDONE ingredient

Market Authorisation Date: 15 October, 2014

Treatment: Dose reduction of pirfenidone by about one half during concurrent administration of ciprofloxacin at a dose of 750 mg twice daily (1500 mg/day) to reduce drug interactions in treatment of a fibrotic, ...

Dosage: CAPSULE;ORAL

How can I launch a generic of ESBRIET before it's drug patent expiration?
More Information on Dosage

ESBRIET family patents

Family Patents

39. Esmolol Hydrochloride Double Strength In Plastic Container patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835505 HQ SPCLT PHARMA Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container
Mar, 2033

(9 years from now)

US8829054 HQ SPCLT PHARMA Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container
Mar, 2033

(9 years from now)

Drugs and Companies using ESMOLOL HYDROCHLORIDE ingredient

Market Authorisation Date: 07 April, 2016

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER family patents

Family Patents

40. Evomela patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9493582 ACROTECH Alkylated cyclodextrin compositions and processes for preparing and using the same
Feb, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Mar 10, 2023

Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient

Market Authorisation Date: 10 March, 2016

Treatment: NA

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of EVOMELA before it's drug patent expiration?
More Information on Dosage

EVOMELA family patents

Family Patents

41. Evrysdi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9586955 GENENTECH INC Compounds for treating spinal muscular atrophy
Feb, 2033

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) May 27, 2029
New Chemical Entity Exclusivity (NCE) Aug 7, 2025
New Patient Population (NPP) May 27, 2025
M (M) Oct 3, 2026

Drugs and Companies using RISDIPLAM ingredient

NCE-1 date: 2024-08-07

Market Authorisation Date: 07 August, 2020

Treatment: NA

Dosage: FOR SOLUTION;ORAL

More Information on Dosage

EVRYSDI family patents

Family Patents

42. Eysuvis patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10993908 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US10646436 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US9393213 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

US10688045 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US10058511 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

US9827191 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US9056057 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

US9737491 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

US9532955 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

US10940108 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US10945948 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US10857096 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US11219596 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Oct 26, 2023

Drugs and Companies using LOTEPREDNOL ETABONATE ingredient

Market Authorisation Date: 26 October, 2020

Treatment: Administration to the eye of a patient for treatment of dry eye condition; A method for delivering a pharmaceutical agent across a mucosal barrier; A method for treating dry eye in a patient; A method...

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage

EYSUVIS family patents

Family Patents

43. Eysuvis patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11642317 ALCON LABS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

US11596599 ALCON LABS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US11872318 ALCON LABS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Oct 26, 2023

Drugs and Companies using LOTEPREDNOL ETABONATE ingredient

Market Authorisation Date: 26 October, 2020

Treatment: A method for treating dry eye in a patient

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage

EYSUVIS family patents

Family Patents

44. Fetroja patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9238657 SHIONOGI INC Cephalosporin having catechol group
Nov, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 14, 2024
Generating Antibiotic Incentives Now (GAIN) Nov 14, 2029

Drugs and Companies using CEFIDEROCOL SULFATE TOSYLATE ingredient

NCE-1 date: 2028-11-14

Market Authorisation Date: 14 November, 2019

Treatment: Method of treating bacterial infections

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

FETROJA family patents

Family Patents

45. Fintepla patents expiration

FINTEPLA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9603815 ZOGENIX INC Method for the treatment of Dravet syndrome
May, 2033

(9 years from now)

US9549909 ZOGENIX INC Method for the treatment of dravet syndrome
May, 2033

(9 years from now)

US9610260 ZOGENIX INC Method for the treatment of Dravet Syndrome
May, 2033

(9 years from now)

US9603814 ZOGENIX INC Method for the treatment of Dravet syndrome
May, 2033

(9 years from now)

US10478442 ZOGENIX INC Method for the treatment of Dravet Syndrome
May, 2033

(9 years from now)

US10478441 ZOGENIX INC Method for the treatment of Dravet syndrome
May, 2033

(9 years from now)

US9610260

(Pediatric)

ZOGENIX INC Method for the treatment of Dravet Syndrome
Nov, 2033

(9 years from now)

US10478441

(Pediatric)

ZOGENIX INC Method for the treatment of Dravet syndrome
Nov, 2033

(9 years from now)

US10478442

(Pediatric)

ZOGENIX INC Method for the treatment of Dravet Syndrome
Nov, 2033

(9 years from now)

US9603814

(Pediatric)

ZOGENIX INC Method for the treatment of Dravet syndrome
Nov, 2033

(9 years from now)

US9549909

(Pediatric)

ZOGENIX INC Method for the treatment of dravet syndrome
Nov, 2033

(9 years from now)

US9603815

(Pediatric)

ZOGENIX INC Method for the treatment of Dravet syndrome
Nov, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Mar 25, 2029
New Indication (I) Mar 25, 2025
Pediatric Exclusivity (PED) Sep 25, 2029

Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient

Market Authorisation Date: 25 June, 2020

Treatment: Use in combination with stiripentol, valproate, and clobazam for the treatment of seizures associated with dravet syndrome; Use in combination with stiripentol for the treatment of seizures associated...

Dosage: SOLUTION;ORAL

How can I launch a generic of FINTEPLA before it's drug patent expiration?
More Information on Dosage

FINTEPLA family patents

Family Patents

46. Genvoya patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8754065

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(8 years from now)

US9296769

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(8 years from now)

US10039718

(Pediatric)

GILEAD SCIENCES INC Use of solid carrier particles to improve the processability of a pharmaceutical agent
Apr, 2033

(9 years from now)

Drugs and Companies using COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Market Authorisation Date: 05 November, 2015

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of GENVOYA before it's drug patent expiration?
More Information on Dosage

GENVOYA family patents

Family Patents

47. Givlaari patents expiration

Can you believe GIVLAARI received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10125364 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
Mar, 2033

(9 years from now)

US9133461 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
Nov, 2033

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9631193 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
Mar, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 20, 2024
Orphan Drug Exclusivity (ODE) Nov 20, 2026

Drugs and Companies using GIVOSIRAN SODIUM ingredient

NCE-1 date: 2023-11-21

Market Authorisation Date: 20 November, 2019

Treatment: Treatment of acute hepatic porphyria

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

GIVLAARI family patents

Family Patents

48. Harvoni patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9393256

(Pediatric)

GILEAD SCIENCES INC Methods for treating HCV
Mar, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 28, 2026

Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient

Market Authorisation Date: 28 August, 2019

Treatment: NA

Dosage: PELLETS;ORAL

More Information on Dosage

HARVONI family patents

Family Patents

49. Hepzato patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10195334 DELCATH SYSTEMS INC Filter and frame apparatus and method of use
Jan, 2033

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Aug 14, 2026
Orphan Drug Exclusivity (ODE) Aug 14, 2030

Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient

Market Authorisation Date: 14 August, 2023

Treatment: NA

Dosage: POWDER;INTRA-ARTERIAL

More Information on Dosage

HEPZATO family patents

Family Patents

50. Hetlioz patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9060995 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10149829 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

USRE46604 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10610510 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10945988 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11285129 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11633377 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US9855241 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10449176 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US9549913 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US9539234 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11833130 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11850229 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10980770 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 1, 2027

Drugs and Companies using TASIMELTEON ingredient

Market Authorisation Date: 31 January, 2014

Treatment: Treatment of non-24-hour sleep-wake disorder by avoiding the use of tasimelteon in combination with fluvoxamine; Treatment of non-24 hour sleep-wake disorder by avoiding the use of tasimelteon in comb...

Dosage: CAPSULE;ORAL

How can I launch a generic of HETLIOZ before it's drug patent expiration?
More Information on Dosage

HETLIOZ family patents

Family Patents

51. Hetlioz Lq patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9539234 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10149829 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10980770 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11285129 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10610510 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11633377 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11850229 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11833130 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 1, 2027

Drugs and Companies using TASIMELTEON ingredient

Market Authorisation Date: 01 December, 2020

Treatment: Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the avoiding the use of tasimelteon in combination with a strong cyp1a2 inhibitor; Treatment of nighttime sleep disturba...

Dosage: SUSPENSION;ORAL

More Information on Dosage

HETLIOZ LQ family patents

Family Patents

52. Ibsrela patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8541448 ARDELYX INC Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
Aug, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 12, 2024

Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient

NCE-1 date: 2023-09-13

Market Authorisation Date: 12 September, 2019

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

IBSRELA family patents

Family Patents

53. Iclusig patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9493470 TAKEDA PHARMS USA Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
Dec, 2033

(9 years from now)

US11384086 TAKEDA PHARMS USA Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1- yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
Dec, 2033

(9 years from now)

US11192897 TAKEDA PHARMS USA Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
Dec, 2033

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11192895 TAKEDA PHARMS USA Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
Dec, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Dec 18, 2023

Drugs and Companies using PONATINIB HYDROCHLORIDE ingredient

Market Authorisation Date: 14 December, 2012

Treatment: A method for treating philadelphia chromosome positive acute lymphoblastic leukemia; A method for treating leukemia resulting from a mutation in the bcr-abl kinase domain; A method for treating chroni...

Dosage: TABLET;ORAL

How can I launch a generic of ICLUSIG before it's drug patent expiration?
More Information on Dosage

ICLUSIG family patents

Family Patents

54. Idhifa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9512107 CELGENE CORP Therapeutically active compositions and their methods of use
Jan, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10294215 CELGENE CORP Therapeutically active compounds and their methods of use
Jan, 2033

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 1, 2024

Drugs and Companies using ENASIDENIB MESYLATE ingredient

Market Authorisation Date: 01 August, 2017

Treatment: Treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation

Dosage: TABLET;ORAL

More Information on Dosage

IDHIFA family patents

Family Patents

55. Imbruvica patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10125140 PHARMACYCLICS INC Crystalline forms of a bruton's tyrosine kinase inhibitor
Jun, 2033

(9 years from now)

US10106548 PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Jun, 2033

(9 years from now)

US9725455 PHARMACYCLICS INC Crystalline forms of a bruton's tyrosine kinase inhibitor
Jun, 2033

(9 years from now)

US9296753 PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Oct, 2033

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10752634 PHARMACYCLICS INC Crystalline forms of a brutons tyrosine kinase inhibitor
Jun, 2033

(9 years from now)

US10294231 PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Jun, 2033

(9 years from now)

US9713617 PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Jun, 2033

(9 years from now)

US10294232 PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Jun, 2033

(9 years from now)

US10961251 PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Jun, 2033

(9 years from now)

US9540382 PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Aug, 2033

(9 years from now)

US9713617

(Pediatric)

PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Dec, 2033

(9 years from now)

US10106548

(Pediatric)

PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Dec, 2033

(9 years from now)

US10961251

(Pediatric)

PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Dec, 2033

(9 years from now)

US10752634

(Pediatric)

PHARMACYCLICS INC Crystalline forms of a brutons tyrosine kinase inhibitor
Dec, 2033

(9 years from now)

US9725455

(Pediatric)

PHARMACYCLICS INC Crystalline forms of a bruton's tyrosine kinase inhibitor
Dec, 2033

(9 years from now)

US10125140

(Pediatric)

PHARMACYCLICS INC Crystalline forms of a bruton's tyrosine kinase inhibitor
Dec, 2033

(9 years from now)

US10294231

(Pediatric)

PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Dec, 2033

(9 years from now)

US10294232

(Pediatric)

PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Dec, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 24, 2029
New Product (NP) Aug 24, 2025
Pediatric Exclusivity (PED) Feb 24, 2026

Drugs and Companies using IBRUTINIB ingredient

Market Authorisation Date: 24 August, 2022

Treatment: Treatment of marginal zone lymphoma; Treatment of mantle cell lymphoma; Treatment of chronic lymphocytic leukemia; Treatment of small lymphocytic lymphoma; Treatment of waldenstrom's macroglobulinemia

Dosage: SUSPENSION;ORAL

How can I launch a generic of IMBRUVICA before it's drug patent expiration?
More Information on Dosage

IMBRUVICA family patents

Family Patents

56. Imvexxy patents expiration

IMVEXXY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11116717 THERAPEUTICSMD INC Soluble estradiol capsule for vaginal insertion
Jun, 2033

(9 years from now)

US11123283 THERAPEUTICSMD INC Soluble estradiol capsule for vaginal insertion
Jun, 2033

(9 years from now)

US10471072 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods
Jun, 2033

(9 years from now)

US10668082 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods
Jun, 2033

(9 years from now)

US10568891 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods
Jun, 2033

(9 years from now)

US10888516 THERAPEUTICSMD INC Soluble estradiol capsule for vaginal insertion
Jun, 2033

(9 years from now)

US11065197 THERAPEUTICSMD INC Soluble estradiol capsule for vaginal insertion
Jun, 2033

(9 years from now)

US10258630 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods
Dec, 2033

(9 years from now)

US9180091 THERAPEUTICSMD INC Soluble estradiol capsule for vaginal insertion
Dec, 2033

(9 years from now)

US10398708 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods
Dec, 2033

(9 years from now)

Drugs and Companies using ESTRADIOL ingredient

Market Authorisation Date: 29 May, 2018

Treatment: Treatment of a symptom of vulvar and vaginal atrophy; Treatment of dyspareunia; Treatment of moderate to severe dyspareunia

Dosage: INSERT;VAGINAL

How can I launch a generic of IMVEXXY before it's drug patent expiration?
More Information on Dosage

IMVEXXY family patents

Family Patents

57. Infugem patents expiration

INFUGEM's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9241948 SUN PHARM Ready to be infused gemcetabine solution
Jul, 2033

(9 years from now)

Drugs and Companies using GEMCITABINE HYDROCHLORIDE ingredient

Market Authorisation Date: 16 July, 2018

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

INFUGEM family patents

Family Patents

58. Inveltys patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9393213 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

US10646437 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US10688045 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US9827191 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US9737491 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

US10864219 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US11219597 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US10058511 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

US9532955 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

US9056057 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

Drugs and Companies using LOTEPREDNOL ETABONATE ingredient

Market Authorisation Date: 22 August, 2018

Treatment: A method for treating inflammation and/or other disorders in an eye of a patient; A method for delivering a pharmaceutical agent across a mucosal barrier; A method for treating ocular inflammation; A ...

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage

INVELTYS family patents

Family Patents

59. Inveltys patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11642317 ALCON LABS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

US11872318 ALCON LABS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

Drugs and Companies using LOTEPREDNOL ETABONATE ingredient

Market Authorisation Date: 22 August, 2018

Treatment: NA

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage

INVELTYS family patents

Family Patents

60. Ionsys patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9095706 THE MEDICINES CO Self-test for analgesic product
Feb, 2033

(8 years from now)

Drugs and Companies using FENTANYL HYDROCHLORIDE ingredient

Market Authorisation Date: 22 May, 2006

Treatment: NA

Dosage: SYSTEM;IONTOPHORESIS, TRANSDERMAL

More Information on Dosage

IONSYS family patents

Family Patents

61. Jentadueto Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9555001 BOEHRINGER INGELHEIM Pharmaceutical composition and uses thereof
Mar, 2033

(9 years from now)

US9555001

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition and uses thereof
Sep, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Jun 20, 2026
Pediatric Exclusivity (PED) Dec 20, 2026

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 27 May, 2016

Treatment: Method of treating type 2 diabetes in patients with insufficient glycemic control despite therapy with one or more conventional antihyperglycemic agents by administering linagliptin in combination wit...

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of JENTADUETO XR before it's drug patent expiration?
More Information on Dosage

JENTADUETO XR family patents

Family Patents

62. Kalydeco patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11752106 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof
Feb, 2033

(9 years from now)

US8883206 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof
Feb, 2033

(9 years from now)

US10272046 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof
Feb, 2033

(9 years from now)

US11147770 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof
Feb, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) May 3, 2030
New Patient Population (NPP) May 3, 2026

Drugs and Companies using IVACAFTOR ingredient

Market Authorisation Date: 17 March, 2015

Treatment: Treatment of cf in a patient age 1 month to <6 years who has at least one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data using the composition r...

Dosage: GRANULE;ORAL

How can I launch a generic of KALYDECO before it's drug patent expiration?
More Information on Dosage

KALYDECO family patents

Family Patents

63. Kengreal patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8680052 CHIESI Methods of treating, reducing the incidence of, and/or preventing ischemic events
Mar, 2033

(9 years from now)

Drugs and Companies using CANGRELOR ingredient

Market Authorisation Date: 22 June, 2015

Treatment: Method comprising iv administration of cangrelor before pci then continuous infusion for at least 2 hours or the duration of pci and, during or after continuous infusion, administration of a loading d...

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of KENGREAL before it's drug patent expiration?
More Information on Dosage

KENGREAL family patents

Family Patents

64. Korlym patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10500216 CORCEPT THERAP Optimizing mifepristone absorption
Mar, 2033

(9 years from now)

Drugs and Companies using MIFEPRISTONE ingredient

Market Authorisation Date: 17 February, 2012

Treatment: Treating cushing's syndrome

Dosage: TABLET;ORAL

How can I launch a generic of KORLYM before it's drug patent expiration?
More Information on Dosage

KORLYM family patents

Family Patents

65. Kuvan patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9216178

(Pediatric)

BIOMARIN PHARM Dry blend formulation of tetrahydrobiopterin
May, 2033

(9 years from now)

Drugs and Companies using SAPROPTERIN DIHYDROCHLORIDE ingredient

Market Authorisation Date: 19 December, 2013

Treatment: NA

Dosage: POWDER;ORAL

How can I launch a generic of KUVAN before it's drug patent expiration?
More Information on Dosage

KUVAN family patents

Family Patents

66. Kyprolis patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9493582 ONYX THERAP Alkylated cyclodextrin compositions and processes for preparing and using the same
Feb, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Aug 20, 2023

Drugs and Companies using CARFILZOMIB ingredient

Market Authorisation Date: 20 July, 2012

Treatment: NA

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of KYPROLIS before it's drug patent expiration?
More Information on Dosage

KYPROLIS family patents

Family Patents

67. Kyzatrex patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11617758 MARIUS PHARMS LLC Emulsion formulations
Mar, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Jul 27, 2025

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Market Authorisation Date: 27 July, 2022

Treatment: Method of treating testosterone deficiency

Dosage: CAPSULE;ORAL

More Information on Dosage

KYZATREX family patents

Family Patents

68. Liletta patents expiration

LILETTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11090186 MEDICINES360 Methods for using intrauterine systems and IUD insertion devices
Oct, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Jun 29, 2026

Drugs and Companies using LEVONORGESTREL ingredient

Market Authorisation Date: 26 February, 2015

Treatment: A method for prevention of pregnancy

Dosage: INTRAUTERINE DEVICE;INTRAUTERINE

More Information on Dosage

LILETTA family patents

Family Patents

69. Linzess patents expiration

LINZESS's oppositions filed in EPO
Can you believe LINZESS received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9708371 ALLERGAN Treatments for gastrointestinal disorders
Aug, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Jun 12, 2026

Drugs and Companies using LINACLOTIDE ingredient

Market Authorisation Date: 30 August, 2012

Treatment: Method of treating irritable bowel syndrome with constipation in adult patients.; Method of treating chronic idiopathic constipation in adult patients.

Dosage: CAPSULE;ORAL

How can I launch a generic of LINZESS before it's drug patent expiration?
More Information on Dosage

LINZESS family patents

Family Patents

70. Lokelma patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10695365 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Oct, 2033

(9 years from now)

US9913860 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Oct, 2033

(9 years from now)

US8877255 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Oct, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 18, 2023
M (M) Apr 24, 2023

Drugs and Companies using SODIUM ZIRCONIUM CYCLOSILICATE ingredient

NCE-1 date: 2022-05-18

Market Authorisation Date: 18 May, 2018

Treatment: Treatment of hyperkalemia in adults

Dosage: FOR SUSPENSION;ORAL

How can I launch a generic of LOKELMA before it's drug patent expiration?
More Information on Dosage

LOKELMA family patents

Family Patents

71. Lonhala Magnair Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9604018 SUNOVION RESP Aerosol therapy device
May, 2033

(9 years from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Market Authorisation Date: 05 December, 2017

Treatment: NA

Dosage: SOLUTION;INHALATION

More Information on Dosage

LONHALA MAGNAIR KIT family patents

Family Patents

72. Lorbrena patents expiration

Can you believe LORBRENA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8680111 PFIZER Macrocyclic derivatives for the treatment of diseases
Mar, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Mar 3, 2028
New Indication (I) Mar 3, 2024

Drugs and Companies using LORLATINIB ingredient

Market Authorisation Date: 02 November, 2018

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

LORBRENA family patents

Family Patents

73. Luzu patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9199977 BAUSCH Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal
Sep, 2033

(9 years from now)

US9012484 BAUSCH Crystal and pharmaceutical preparation containing the same crystal
Sep, 2033

(9 years from now)

US9453006 BAUSCH Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient
Sep, 2033

(9 years from now)

Drugs and Companies using LULICONAZOLE ingredient

Market Authorisation Date: 14 November, 2013

Treatment: Treatment of fungal infections

Dosage: CREAM;TOPICAL

More Information on Dosage

LUZU family patents

Family Patents

74. Lytgobi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9108973 TAIHO ONCOLOGY 3,5-disubstituted alkynylbenzene compound and salt thereof
Feb, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 30, 2027
Orphan Drug Exclusivity (ODE) Sep 30, 2029

Drugs and Companies using FUTIBATINIB ingredient

NCE-1 date: 2026-09-30

Market Authorisation Date: 30 September, 2022

Treatment: Method of treating intrahepatic cholangiocarcinoma

Dosage: TABLET;ORAL

More Information on Dosage

LYTGOBI family patents

Family Patents

75. Mekinist patents expiration

MEKINIST's oppositions filed in EPO
Can you believe MEKINIST received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10869869 NOVARTIS Method of adjuvant cancer treatment
Aug, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Mar 16, 2030
New Indication (I) Jun 22, 2025
Pediatric Exclusivity (PED) Dec 22, 2025

Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient

Market Authorisation Date: 29 May, 2013

Treatment: Mekinist(r) is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fda-approved test, and involvement o...

Dosage: TABLET;ORAL

More Information on Dosage

MEKINIST family patents

Family Patents

76. Mektovi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9562016 ARRAY BIOPHARMA INC Preparation of and formulation comprising a MEK inhibitor
Oct, 2033

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9980944 ARRAY BIOPHARMA INC Preparation of and formulation comprising a MEK inhibitor
Oct, 2033

(9 years from now)

US9598376 ARRAY BIOPHARMA INC Preparation of and formulation comprising a MEK inhibitor
Oct, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 27, 2025
New Indication (I) Oct 11, 2026

Drugs and Companies using BINIMETINIB ingredient

Market Authorisation Date: 27 June, 2018

Treatment: Treatment of melanoma with a braf mutation; Method of treating melanoma

Dosage: TABLET;ORAL

How can I launch a generic of MEKTOVI before it's drug patent expiration?
More Information on Dosage

MEKTOVI family patents

Family Patents

77. Miebo patents expiration

MIEBO Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10449164 BAUSCH AND LOMB INC Methods of treating ocular disorders using semifluorinated alkanes
Sep, 2033

(9 years from now)

US10576154 BAUSCH AND LOMB INC Semifluorinated alkane compositions
Sep, 2033

(9 years from now)

US10058615 BAUSCH AND LOMB INC Semifluorinated alkane compositions
Sep, 2033

(9 years from now)

US10369117 BAUSCH AND LOMB INC Compositions comprising mixtures of semifluorinated alkanes
Sep, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 18, 2028

Drugs and Companies using PERFLUOROHEXYLOCTANE ingredient

NCE-1 date: 2027-05-19

Market Authorisation Date: 18 May, 2023

Treatment: Treatment of the signs and symptoms of dry eye disease (ded)

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage

MIEBO family patents

Family Patents

78. Mitigare patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9399036 HIKMA INTL PHARMS Methods of colchicine administration
Aug, 2033

(9 years from now)

US8927607 HIKMA INTL PHARMS Methods of colchicine administration
Aug, 2033

(9 years from now)

US9675613 HIKMA INTL PHARMS Methods of colchicine administration
Aug, 2033

(9 years from now)

US9789108 HIKMA INTL PHARMS Methods of colchicine administration
Aug, 2033

(9 years from now)

US9555029 HIKMA INTL PHARMS Methods of colchicine administration
Aug, 2033

(9 years from now)

Drugs and Companies using COLCHICINE ingredient

Market Authorisation Date: 26 September, 2014

Treatment: Method of using colchicine for the prophylaxis of gout flares

Dosage: CAPSULE;ORAL

How can I launch a generic of MITIGARE before it's drug patent expiration?
More Information on Dosage

MITIGARE family patents

Family Patents

79. Myfembree patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11795178 MYOVANT SCIENCES Compositions of thienopyrimidine derivatives
Sep, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 18, 2025
New Product (NP) May 26, 2024
M (M) Jan 27, 2026
New Indication (I) Aug 5, 2025

Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient

NCE-1 date: 2024-12-18

Market Authorisation Date: 26 May, 2021

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

MYFEMBREE family patents

Family Patents

80. Naftin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10166205 SEBELA IRELAND LTD Topical compositions and methods for making and using same
Jan, 2033

(8 years from now)

US8778365 SEBELA IRELAND LTD Topical compositions and methods for making and using same
Jan, 2033

(8 years from now)

US9161914 SEBELA IRELAND LTD Topical compositions and methods for making and using same
Jan, 2033

(8 years from now)

US10729667 SEBELA IRELAND LTD Topical compositions and methods for making and using same
Jan, 2033

(8 years from now)

US10695303 SEBELA IRELAND LTD Topical compositions and methods for making and using same
Jan, 2033

(8 years from now)

US10166206 SEBELA IRELAND LTD Topical compositions and methods for making and using same
Jan, 2033

(8 years from now)

Drugs and Companies using NAFTIFINE HYDROCHLORIDE ingredient

Market Authorisation Date: 27 June, 2013

Treatment: Treatment of fungal infections

Dosage: GEL;TOPICAL

How can I launch a generic of NAFTIN before it's drug patent expiration?
More Information on Dosage

NAFTIN family patents

Family Patents

81. Natroba patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9895388 PARAPRO LLC Methods and compositions useful for controlling cutaneous mites
Nov, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Apr 28, 2024

Drugs and Companies using SPINOSAD ingredient

Market Authorisation Date: 18 January, 2011

Treatment: The product composition (natroba) is for the topical treatment of human scabies mite infestations by melting and delivering the active ingredient, spinosad, to the stratum corneum where scabies mites ...

Dosage: SUSPENSION;TOPICAL

More Information on Dosage

NATROBA family patents

Family Patents

82. Noxafil patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9493582 MERCK SHARP DOHME Alkylated cyclodextrin compositions and processes for preparing and using the same
Feb, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) May 31, 2024
Orphan Drug Exclusivity (ODE) Jun 17, 2028
New Indication (I) Jun 17, 2024

Drugs and Companies using POSACONAZOLE ingredient

Market Authorisation Date: 13 March, 2014

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of NOXAFIL before it's drug patent expiration?
More Information on Dosage

NOXAFIL family patents

Family Patents

83. Nubeqa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8975254 BAYER HEALTHCARE Androgen receptor modulating compounds
Mar, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 30, 2024
New Indication (I) Aug 5, 2025

Drugs and Companies using DAROLUTAMIDE ingredient

NCE-1 date: 2023-07-31

Market Authorisation Date: 30 July, 2019

Treatment: Treatment of patients with non-metastatic castration resistant prostate cancer

Dosage: TABLET;ORAL

More Information on Dosage

NUBEQA family patents

Family Patents

84. Nurtec Odt patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8759372 PFIZER N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta[b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylate salt
Feb, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 27, 2025
New Indication (I) May 27, 2024

Drugs and Companies using RIMEGEPANT SULFATE ingredient

NCE-1 date: 2024-02-28

Market Authorisation Date: 27 February, 2020

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage

NURTEC ODT family patents

Family Patents

85. Ocaliva patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10174073 INTERCEPT PHARMS INC Preparation and uses of obeticholic acid
Jun, 2033

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238673 INTERCEPT PHARMS INC Preparation and uses of obeticholic acid
Jun, 2033

(9 years from now)

US10047117 INTERCEPT PHARMS INC Preparation and uses of obeticholic acid
Sep, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) May 27, 2023